Premium
Inhibition of Fibrinolytic and Thromboplastic Activity by Trasylol®
Author(s) -
AMRIS C. J.
Publication year - 1966
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1966.tb00622.x
Subject(s) - plasmin , fibrinolysis , fibrinogen , coagulation , aprotinin , pharmacology , chemistry , in vivo , antifibrinolytic , thrombin , thromboplastin , medicine , biochemistry , tranexamic acid , biology , platelet , surgery , enzyme , microbiology and biotechnology , blood loss
Trasylol has strong inhibiting effect on the fibrinolytic, fibrinogenolytic and pro‐teolytic activity of plasmin. It also delays and inhibits the thrombin and thrombo‐plastin generation in vitro. Also the activity of preformed thromboplastin is inhibited whereas the thrombin‐fibrinogen reaction is unaffected by Trasylol. Clinical studies of patients with fibrinolysis, hypercoagulability and suspected intravascular coagulation indicate that the antithromboplastic effect of Trasylol also is effective in vivo. The combined antifibrinolytic and antithromboplastic effect of Trasylol may be a new aspect of great importance in the treatment and prophylaxis of induced haemostatic disorders.